

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

www.irjponline.com ISSN 2230 - 8407

Research Article

SYNTHESIS, MOLECULAR DOCKING STUDIES AND ANTIMICROBIAL ACTIVITY OF MANNICH BASES OF THIAZOLIDINE-2,4-DIONES

Swapna D ^{1*}, Rajitha G², Umamaheswari A ³ and Sudheer Kumar K³

¹Department of Pharmaceutical Chemistry, MNR College of Pharmacy, Fasalwadi, Sangareddy-502294, Telangana, India ²Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women's University), Tirupati-517502, Andhra Pradesh, India

³Department of Bioinformatics, Sri Venkateswara Institute of Medical Sciences, Tirupati-517502, Andhra Pradesh, India *Corresponding Author Email: swapna.dvnn@gmail.com

Article Received on: 02/10/18 Approved for publication: 02/11/18

DOI: 10.7897/2230-8407.0911274

ABSTRACT

The aim of study was to synthesize a new series of mannich bases of thiazolidine-2,4-diones. A new series of mannich bases of thiazolidine-2,4-diones have been synthesized by mannich base reaction between 5-substituted thiazolidine-2,4-dione, acetanilide and aromatic aldehydes. The structure of these compounds was established by IR, HNMR and Mass spectrosopy. The synthesized mannich bases of thiazolidine-2,4-diones were subjected to molecular docking studies with dihydropteroate synthase (DPHS, PDB ID: 3TYE) by using XP GLIDE module of Schrodinger suite and *in silico* studies by molinspiration online tool. These new compounds (3a-3i) were evaluated for their antimerobial activity. The compounds 3g and 3h showed good activity against bacteria Salmonella paratyphi, Escherichia coli and fungi Aspergillus niger, Colletotrichum coffeanum comparable to that of standard drugs streptomycin and griseofulvin. Molecular docking studies showed the compound 3h showed good docking score of -5.419 with target protein dihydropteroate synthase.

Keywords: Thiazolidine-2,4-diones, Antimicrobial activity, Mannich base, Molecular docking

INTRODUCTION

Development of novel synthetic antimicrobial agents is an important and challenging problem because, microorganisms have developed resistance to available antibiotics in the market. Hence it is essential to develop new compounds for treating infectious disease1. Thiazolidine-2,4diones (TZDs) are important class of heterocyclic compounds, because of their various biological applications such as antihyperglycemic²⁻⁴, tuberculostatic5, anti-inflammatory6, bactericidal⁷⁻⁸, fungicidal⁹etc. The reported potential activities of "glitazones" initiated us to synthesize N-substituted-2,4-TZD derivatives with good antimicrobial activity.

MATERIALS AND METHODS

The chemicals and reagents were procured from sigma aldrich. By using open capillary tubes melting points were determined and are uncorrected. Purity of the all synthesized compounds was checked by using precoated TLC plates and iodine was used as visualizing agent. IR spectra were recorded on FT-IR 8400S, Fourier Transform (Shimadzu) Infrared spectrophotometer using KBr pellet method. ¹H NMR spectra were recorded on Bruker AVANCE (400 MHz) spectrophotometer in dimethyl sulfoxide (DMSO) using tetramethylsilane (TMS) as an internal standard. The mass spectra were recorded on Shimadzu LCMS-8030 Mass Spectrometer. Elemental analyses (C, H, and N) were performed using Perkin Elmer model 240 C analyzer.

Experimental Procedure

The schematic representation of synthesized compounds (3a–3i) were summarized in Figure 1. The physical data of synthesized compounds (3a-3i) were given in Table 1.

Synthesis of Thiazolidine-2,4-dione (1)

56.5 g of chloroacetic acid (0.6 mol) in a 60 ml of water and 45.6 g of thiourea (0.6mol) in 60 ml of water were transferred into a 250 ml round bottomed flask. The reaction mixture was stirred and cooled to form a white precipitate. To contents of the flask, added slowly 60 ml concentrated hydrochloric acid. The reaction mixture was stirred and refluxed for 8-10 hours at 100-110°C. Cooled content of the flask solidified to mass of cluster of white needles. The product was filtered and washed with water to remove traces of HCl and dried. It was recrystallized from ethanol. Yield: 73%; m.p: 124 – 126°C.

Synthesis of 5-(thiophen-2-ylmethylene) thiazolidine-2,4-dione (2a)

Into a 250 ml round bottomed flask thiophen-2-carbaldehyde (20 g, 0.188 mol) and 2,4-thiazolidinedione (22 g, 0.188 mol) were transferred and added dry toluene and 1 ml of piperidine. The reaction mixture was refluxed for 1 hour with stirring. Cooled the product, precipitate was obtained. The compound was filtered and washed with cold, dry toluene and dry ethanol. Yield: 68%; m.p: $236-238^{\circ}\text{C}$.

Similarly compounds 2b - 2i were prepared by adopting similar procedure using appropriate substituted aldehydes.

Synthesis of 3-(4-(dimethylamino) phenyl)-3-(2,4-dioxo-5-(thiophen-2-ylmethylene)thiazolidin-3-yl)-N-phenylpropanamide (3a)

In a 250 ml round bottomed flask 5-(thiophen-2-ylmethylene) thiazolidine-2,4-dione (2a) (0.1 mol), 4-dimethyl amino benzaldehyde (0.1 mol) and acetanilide (0.1 mol) were suspended in an ethanol. The reaction mixture was refluxed for 5 hours. The reaction mixture was cooled and poured into ice cold water and precipitate was separated by filtration and dried. It was recrystallized from absolute ethanol¹⁰⁻¹¹.

Similarly compounds 3b - 3i were prepared by adopting similar procedure using appropriate aromatic aldehydes.

3-(4-(dimethylamino)phenyl)-3-(2,4-dioxo-5-(thiophen-2-ylmethylene)thiazolidin-3-yl)-N-phenylpropanamide(3a):

Yield: 78%; m.p: 231-233°C; IR (KBr, $v_{max, Cm}^{-1}$) 3427 (NH), 3038 (Ar C-H), 1721 (C=O), 1333 (C-N), 684 (C-S); H NMR (400 MHz, DMSO – d₆) δ: 2.08 (s, 1H, CH), 2.52 (s, 6H, N(CH₃)₂), 4.18 (s, 2H, CH₂), 7.52–8.16 (m, 12H, Ar C-H), 7.82 (s, 1H, R-CH=C), 10.03 (s, 1H, NH); EI-MS m/z: 478 (M+1); Anal. Calcd. For C₂₅H₂₃N₃O₃S₂: C, 62.87; H, 4.85; N, 8.8; Found: C, 62.42; H, 4.16; N, 8.6.

3-(2,4-dioxo-5-(thiophen-2-ylmethylene)thiazolidin-3-yl)-3-(4-nitrophenyl)-N-phenylpropanamide (3b):

Yield: 70%;m.p: $26\bar{1}$ - 263° C;IR (KBr, $\nu_{max, Cm}^{-1}$) 3467 (NH), 3086 (Ar C-H), 1709 (C=O), 1356 (C-N), 687 (C-S); ¹H NMR (400 MHz, DMSO – d_6) δ: 2.28 (s, 1H, CH), 4.18 (s, 2H, CH₂), 7.40–7.80 (m, 12H, Ar C-H), 7.33 (s, 1H, R-CH=C), 10.09 (s,1H,NH); EI-MS m/z: 480 (M+1); Anal. Calcd. For $C_{23}H_{17}N_3O_5S_2$: C, 57.61; H, 3.57; N, 8.76; Found: C, 57.42; H, 3.16; N, 8.4.

3-(2,4-dioxo-5-(thiophen-2-ylmethylene)thiazolidin-3-yl)-3-(4-methylphenyl)-N-phenylpropanamide(3c):

Yield: 78%; m.p: 251-253 °C; IR (KBr, $v_{max, Cm}^{-1}$) 3456 (NH), 3112 (Ar C-H), 1714 (C=O), 1346 (C-N), 678 (C-S); ¹H NMR (400 MHz, DMSO – d₆) δ: 2.19 (s, 1H, CH), 3.52 (s, 3H, CH₃), 4.19 (s, 2H, CH₂), 7.62–8.24 (m, 12 H, Ar C-H), 8.51 (s, 1H, R-CH=C), 10.34 (s, 1H, NH); EI-MS m/z: 449 (M+1); Anal. Calcd. For C₂₄H₂₀N₂O₃S₂: C, 64.26; H, 4.49; N, 6.25; Found: C, 64; H, 4.36; N, 6.19.

3-(2,4-dioxo-5-(thiophen-2-ylmethylene)thiazolidin-3-yl) 3-(4-chlorophenyl)-N-phenylpropanamide(3d):

Yield: 67%;m.p: $206-208^{\circ}$ C; IR (KBr, $v_{max, Cm}^{-}$ 1) 3456 (NH), 3077 (Ar C-H), 1679 (C=O), 1326 (C-N), 682 (C-S); 1 H NMR (400 MHz, DMSO – d_{6}) δ : 2.08 (s, 1H, CH),4.14 (s, 2H, CH₂), 7.62-7.90 (m, 12 H, Ar C-H), 7.59 (s, 1H, R-CH=C), 11.01 (s, 1H, NH). EI-MS m/z: 470 (M+1); Anal. Calcd. For $C_{23}H_{17}N_{2}O_{3}S_{2}$ Cl: C, 58.9; H, 3.65; N, 5.97; Found: C, 58.42; H, 3.16; N, 5.89.

3-(2,4-dioxo-5-(thiophen-2-ylmethylene)thiazolidin-3-yl)-3-(4-methoxyphenyl)-N-phenylpropanamide(3e):

Yield:75%; m.p: 227-229°C; lR (KBr, ν_{max, Cm}-1) 3447 (NH), 3126 (Ar C-H), 1682 (C=O), 1378 (C-N), 646 (C-S); ¹H NMR (400 MHz,DMSO – d₆) δ:2.08 (s, 1H, CH),3.76 (s, 3H, OCH₃), 4.21 (s, 2H, CH₂), 7.62–7.90 (m, 12 H, Ar C-H), 8.19 (s, 1H, R-CH=C), 11.11 (s, 1H, NH); EI-MS m/z: 466 (M+1); Anal. Calcd. For C₂₇H₂₄N₂O₅S: C, 66.38; H, 4.95; N, 5.73; Found: C, 66.34; H, 4.89; N, 5.68.

3-(2,4-dioxo-5-(thiophen-2-ylmethylene)thiazolidin-3-yl)-3-(3,4-dimethoxyphenyl)-N-phenylpropanamide(3f):

Yield: 81%;m.p: 237-238°C; IR (KBr, $v_{max, Cm}^{-1}$) 3398 (NH), 3087 (Ar C-H), 1718 (C=O), 1345 (C-N), 668 (C-S); ¹H NMR (400 MHz,DMSO – d_6) δ : 2.06 (s, 1H, CH), 3.82 (s, 6H, (OCH₃)₂), 4.18 (s, 2H, CH₂), 7.24–7.90 (m, 11 H, Ar C-H) 8.13 (s, 1H, R-CH=C), 10.11 (s, 1H, NH); EI-MS m/z: 495 (M+1); Anal. Calcd. For $C_{25}H_{22}N_2O_5S_2$: C, 60.71; H, 4.48; N, 5.66; Found: C, 60.34; H, 4.39; N, 5.62.

3-(5-(3,4-dimethoxybenzylidene)-2,4-dioxothiazolidin-3-yl)-N,3-diphenylpropanamide(3h):

Yield: 73%; m.p: 218-220°C; IR (KBr, $v_{max, Cm}^{-1}$) 3448 (NH), 3092 (Ar C-H), 1696 (C=O), 1358 (C-N), 688 (C-S); ¹H NMR (400 MHz, DMSO – d_6) δ : 2.18 (s, 1H, CH), 3.62 (s, 6H, (OCH₃)₂), 4.14 (s, 2H, CH₂), 7.24–7.96 (m, 13 H, Ar C-H), 8.23 (s, 1H, R-CH=C), 11.18 (s, 1H, NH); EI-MS m/z: 489 (M+1). Anal. Calcd. For $C_{27}H_{24}N_2O_5S$: C, 66.38; H, 4.95; N, 5.73; Found: C, 66.34; H, 4.89; N, 5.68.

3-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-3-(4-chlorophenyl)-N-phenylpropanamide(3i):

Yield: 74%; m.p.: 234-236°C; IR (KBr, $v_{max, Cm}^{-1}$) 3457 (NH), 3084 (Ar C-H), 1711 (C=O), 1366 (C-N), 677 (C-S); ¹H NMR (400 MHz, DMSO – d_6) δ : 2.18 (s, 1H, CH),4.16 (s, 2H, CH₂), 7.62–7.94 (m, 14 H, Ar C-H), 7.81 (s, 1H, R-CH=C), 10.36 (s, 1H, NH); EI-MS m/z: 450 (M+1). Anal. Calcd. For C₂₄H₁₈N₂O₃SCl: C, 64.07; H, 4.03; N, 6.23; Found: C, 64; H, 4.; N, 6.18.

Molecular docking

Molecular docking studies were performed using various modules of Schrodinger using XP Glide. The 3D X-ray crystal structure of enzyme DHPS (Dihydropteroate synthase) imported in to maestro v 9.0 and receptor grid of 20x20x20 A° with its ligand (PDB ID: 3TYE) was obtained from the Protein Data Bank (PDB). The enzyme was prepared for docking studies involves i) ligand molecule was removed from the enzyme active site. ii) Hydrogen atoms were added to the structure with their standard geometry iii) The obtained model was used in predicting the ligand enzyme interaction at the active site¹²⁻¹⁵.

In silico studies

By using Molinspiration online tool the ADME properties of synthesized compounds were determined. (http://www.molinspiration.com/cgi-bin/properties)¹⁶. The % oral absorption was calculated according to the formula.

$$\text{\%ABS}=109-(0.345 \times TPSA)$$

Lipinski's rule of five (RO5) is used to evaluate whether the chemical compound possess the properties of drug likeness (i.e. orally active) in humans. As per the rule the compound possessing log P in -0.4 to +5.6 range, molar refractivity 40–130, molecular weight 180–500, number of atoms 20–70 and TPSA >140. All the designed compounds obeyed Lipinski rule of five suggesting good oral bioavailability for the title compounds (Table 3). The compounds with bioactivity score>0 are considered to be active and those with scores ranging from -0.5 to 0 are considered to be moderately active¹⁷. (Table 4)

Biological Evaluation of Antimicrobial Activity

The antimicrobial activity of the prepared compounds was determined by cup plate method (Agar diffusion method) by measuring zone of inhibition at a concentration of 50 µg/ml against gram negative Salmonella paratyphi, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, gram positive

Bacillus subtilis, Streptococcus pyogene bacteria and fungi Aspergillus niger, Penicillium notatum and Colletotrichum coffeanum. Streptomycin and Griseofulvin were used as standard drugs at a concentration of $50~\mu g/ml$.

Table 1: Physical data of title compounds 3a - 3i

Compound	Molecular Formula	R	\mathbf{R}_{1}	Molecular Weight (gm)	m.p. (°C)	%Yield	R _f value	
3a	C ₂₅ H ₂₃ N ₃ O ₃ S ₂	s	4-N(CH ₃) ₂	477	231-233	78	0.61	
3b	C ₂₃ H ₁₇ N ₃ O ₅ S ₂	s	4-NO ₂	479	261-263	70	0.74	
3c	C ₂₄ H ₂₀ N ₂ O ₃ S ₂	S	4-CH ₃	448	251-253	78	0.62	
3d	C ₂₃ H ₁₇ N ₂ O ₃ S ₂ Cl	s	4-C1	468	206-208	67	0.63	
3e	C ₂₄ H ₂₀ N ₂ O ₄ S ₂	s	4-OCH ₃	465	227-229	75	0.65	
3f	C ₂₅ H ₂₂ N ₂ O ₅ S ₂	s	3,4-di methoxy	494	237-238	81	0.62	
3g	C ₂₄ H ₂₁ N ₃ O ₃ S ₂	s	4-NHCH ₃	463	232-234	76	0.63	
3h	C ₂₇ H ₂₄ N ₂ O ₅ S	3,4-di methoxy phenyl	Н	488	218-220	73	0.67	
3i	C ₂₄ H ₁₈ N ₂ O ₃ SCl	Phenyl	4-C1	449	234-236	74	0.70	

m.p: Melting point; %Yield: Percentage yield; Rf value: Retention factor;

Table 2: Molecular docking score and binding energy of title compounds 3a-3i

S.No.	DHPS (3TYE) with Compound	Docking score	Binding free energy (kcal/mol)
1	3a	-3.33	-48.116
2	3b	-3.245	-43.26
3	3c	-2.068	-49.498
4	3d	-3.34	-43.246
5	3e	-3.212	-41.88
6	3f	-3.513	-44.27
7	3g	-3.725	-64.84
8	3h	-5.419	-48.673
9	3i	-1.604	-50.018
10	Crystal ligand (XTZ)	-8.332	-63.875

Table 3: Analysis of Lipinski rule of 5 for title compounds 3a-3i

Code	log P	TPSA	% abs	n atoms	MW	n ON	n OHNH	n	n	Molar
	_							Violations	Rotb	volume
3a	4.21	71.41	84	33	477	6	1	0	7	413.95
3b	4.06	114	70	33	479	8	1	0	7	391.38
3c	4.55	68.17	85	31	448	5	1	0	6	384.6
3d	4.78	68.17	85	31	468	5	1	0	6	381.58
3e	4.16	77.41	82	32	465	6	1	0	7	393.59
3f	3.75	86.64	79	34	494	7	1	0	8	419.13
3g	3.96	86.20	79	32	463	6	2	0	7	397.01
3h	3.85	86.84	79	35	489	7	1	0	8	428.42
3i	4.88	68.17	85	32	463	5	1	0	6	390.87

log P: Partition coefficient; TPSA: Topological polar surface area; % abs: percentage of absorption; n atoms: no of atoms; n ON: No. of hydrogen bond acceptors; n OHNH: No. of hydrogen bond donors; n Rotb: No. of rotatable bonds;

Table 4: Bio active scores of title compounds 3a-3i

S. No	Code	GPCR	ICM	KI	NRL	PI	EI
1	3a	-0.48	-0.85	-0.43	-0.74	-0.55	-0.31
2	3b	-0.60	-0.87	-0.57	-0.83	-0.63	-0.38
3	3c	-0.55	-0.94	-0.51	-0.83	-0.61	-0.36
4	3d	-0.52	-0.89	-0.49	-0.82	-0.60	-0.34
5	3e	-0.54	-0.92	-0.49	-0.79	-0.59	-0.35
6	3f	-0.52	-0.88	-0.47	-0.77	-0.59	-0.33
7	3g	-0.47	-0.83	-0.40	-0.77	-0.53	-0.30
8	3h	-0.45	-0.75	-0.41	-0.58	-0.53	-0.28
9	3i	-0.45	-0.73	-0.42	-0.61	-0.53	-0.28

GPCR: G-protein coupled receptor ligand; ICM: Ion Channel Modulator; KI: Kinase Inhibitor; NRL: Nuclear Receptor Ligand; PI: Protease Inhibitor; EI: Enzyme Inhibitor.

Table 5: Antimicrobial activity data of title compounds 3a-3i at 50 µg/ml

S.No	Compound	Zone of inhibition (mm)								
	Code	Gram negative			Gi	ram positive	Fungal			
		SP	PA	EC	PM	BS	S.pyogenes	AN	PN	CC
1	3a	20	19	18	11	15	17	13	17	15
2	3b	NA	NA	15	11	22	17	12	NA	14
3	3c	18	19	NA	18	13	NA	NA	19	11
4	3d	NA	NA	12	NA	13	14	16	16	NA
5	3e	20	18	16	12	20	NA	20	19	22
6	3f	22	9	19	12	10	11	16	13	NA
7	3g	24	20	25	20	21	17	20	19	22
8	3h	26	22	27	21	22	14	21	18	24
9	3i	NA	NA	10	NA	12	16	NA	11	10
10	Streptomycin	30	32	32	33	28	30	NT	NT	NT
11	Griseofulvin	NT	NT	NT	NT	NT	NT	25	30	35

SP: Salmonella paraytphi; PA: Pseudomonas aeruginosa; EC: Escherichia coli; BS: Bacillus subtilis; S.pyogenes: Streptococcus pyogenes; AN: Aspergillus niger; PN: Penicillium notatum; CC: Colletotrichum coffeanum; NT: Not tested; NA: Not Active.

In vitro antimicrobial activity

Cup Plate Method

Antimicrobial activity was performed by cup plate method by measuring zone of inhibition. Muller Hinton agar media for bacterial strain and Sabouraud dextrose agar (SDA) for fungal strain was used as culture medium & dimethyl sulfoxide (DMSO) was used as solvent control. The test organisms were inoculated in nutrient broth and were incubated at 34-37°C for 48 hours, it was stored in refrigerator. The stock culture was maintained. Bacterial and fungal inoculum was prepared by transferring a loop full of stock culture to the nutrient broth in conical flask. The flask was incubated at 34-37°C for 24 hours before experimentation 18-20.

A volume of 25 ml of sterile hot agar medium was poured in each plate and allowed to harden on a level surface. The agar plates were inoculated with 24-hour test inoculums by spreading uniformly with sterile cotton swabs. The plates were then allowed to dry in the inverted position in an incubator for 30 mins. Afterwards they were removed, and bore were made on the medium using sterile borer. A volume of 0.1 ml of test solution was added to respective bores. Streptomycin at a concentration ken as standard drug. A control having only DMSO in the cup was maintained in each plate. The petri plates were kept in the refrigerator at 4°C for 15 mins for diffusion to take place. Afterwards they were incubated at 37°C for 24 hours and zones of inhibition were observed and measured using a scale. Similarly, the antifungal activity of synthesized compounds was determined by cup plate method using Sabouraud dextrose broth and the petri plates were incubated at 37°C for 48 hours and determined the zone of inhibition. Griseofulvin was used as a standard drug at a concentration of 50 µg/ml ²¹⁻²². The various antimicrobial activity results of synthesized compounds were showed in the Table 5.

RESULTS & DISCUSSION

Chemistry

2,4-TZD (1) was synthesized with chloroacetic acid and thiourea in hot water. 5-substituted-2,4-thiazolidinedione (2) was obtained with Knoevenagel condensation of 2,4-TZD (1) and aromatic aldehyde in Toluene in presence of piperidine. A series of 3-(2,4-dioxo-5-(substituted-2-ylmethylene)thiazolidin-3-yl)-3-(substituted phenyl)- N-phenylpropanamide (3a-3i) were synthesized by mannich reaction between 5-(substituted-2-ylmethylene) thiazolidine-2,4-dione (2), aromatic aldehyde and acetanilide in few ml of ethanol.

The structure of the title compounds was elucidated by ¹H NMR, Mass and IR spectroscopy. All spectral data were in accordance with the assumed structures. IR spectra of the compounds (3a-3i) showed NH stretching at 3467-3398 cm-1, aromatic stretching at 3112-3077 cm-1, C=O stretching bonds at 1721-1679 cm-1, C-N stretching at 1378-1326 cm-1 and C-S stretching at 687-646 cm-1 respectively. ¹H NMR spectra of the compounds (3a-3i) showed CH protons at 2.08-2.19 ppm, methylene protons at 4.14-4.18 ppm, aromatic protons at 7.1-7.9 ppm and NH protons at 10.0-11.34 ppm. The mass spectrum of the compounds (3a-3i) showed (M+1) ion peak between 449-495 m/z. The C, H and N analyse of title compounds were in good agreement with the calculated values.

Antimicrobial activity

The compounds (3a-3i) were evaluated for their invitro antimicrobial activity by the agar diffusion (cup plate) method by measuring zone of inhibition. The results of antimicrobial evaluation (Table 5) revealed that some of the compounds showed moderate to good bacterial and fungal inhibition. The

compounds **3g** and **3h** showed good activity against *S. paratyphi* and *E. coli* with zone of inhibition ranging from 24-27 mm. The compounds **3a**, **3e** and **3f** showed moderate activity against *S. paratyphi* with zone of inhibition ranging from 20-22 mm. The compounds **3e**, **3g** and **3h** showed good antifungal activity against *A. niger* and *C. coffeanum* with zone of inhibition ranging from 20-24 mm. The results were in accordance with previous studies, which indicated that 4-hydroxy-3-methoxy and 4-dimethyl amino substituents on benzylidene ring showed good antimicrobial activity⁷.

Molecular docking Studies

Molecular docking studies of title compounds were carried out on target protein DHPS (PDB Id: 3TYE) and the data (Table 2) reveals all the synthesized compounds showed docking scores ranging from -1.604 to -5.419 kcal/mol. The synthesized compound **3h** showed good binding score of -5.419 predicted by

using XP GLIDE. This data provides the type of interactions within the target protein. (Figure 2-3).

In silico studies

Computation of molecular descriptors such as log P, topological surface area, number of hydrogen bond donors and acceptors and the bioactivity scores for G-protein coupled receptor (GPCR) ligand, ion channel modulator, kinase inhibitor, nuclear receptor ligand, protease inhibitor and enzyme inhibitor were calculated by using Molinspiration online tool (http://www.molinspiration.com/cgi-bin/properties). The *in silico* data reports all the compounds obey the Lipinski rule of five. The oral bioavailability of title compounds assessed by Molinspiration online kit, showed good oral bioavailability between 70-85% and also have good bioactive scores towards the ion channel modulator and nuclear receptor ligand than other types of mechanisms. (Table 3 & 4)

 $R = \text{2-Thiophenyl, Phenyl} \\ R_1 = \text{4-N(CH}_3)_2, \text{4-NO}_2, \text{4-CH}_3, \text{4-Cl, 4-OCH}_3, \text{3,4-di methoxy, 4-NHCH}_3, \text{4-H, 4-Cl} \\$

Figure 1: Schematic representation of mannich bases of thiazolidine-2,4-diones




Figure 2: 2D Interaction of standard compound with Active site of 3TYE target

Figure 3: 2D Interaction of 3h compound with Active site of 3TYE

CONCLUSION

Our present work brings forth a method for the synthesis of nine Mannich bases 3a-3i using conventional procedures. The compounds 3g and 3h showed good activity against gram negative bacteria Salmonella paratyphi, Escherichia coli and fungi Aspergillus niger, Colletotrichum coffeanum, comparable to that of standard. These compounds could be selected as a lead compounds for further development of antimicrobial agents.

ACKNOWLEDGEMENTS

The authors are thankful to MNR College of Pharmacy, Sangareddy for providing facility to research work.

REFERENCES

- Alagawadi KR, Shankar GA. Synthesis, characterization and antimicrobial activity evaluation of new 2,4-Thiazolidinediones bearing imidazo[2,1-b] [1,3,4] thiadiazole moiety. Arabian Journal of Chemistry 2011; 4: 465–72. https://doi.org/10.1016/j.arabjc.2010.07.012
- 2. Pattan SR, Kekare P, Ashwini P, Nikalje A, Kittu BS. Studies on the synthesis of novel 2,4-thiazolidinedione derivatives with antidiabetic activity. Iranian Journal of Pharmaceutical Sciences 2009; 5 (4): 225-30.
- 3. Anna Pratima GN, Dipali D, Hemant DU. Facile synthesis and in vivo hypoglycemic activity of novel 2,4-thiazolidinedione derivatives. European Journal of Experimental Biology 2012; 2 (2): 343-53.
- Ramakrishna V, Saileela R, Ravindranath LK. Novel Route for synthesis of antihyperglycaemic activity of thiazolidine 2,4-dione derivatives as a mannich bases. Organic and Medicinal Chemistry International Journal 2017; 3 (2).
- Pattan S, Kedar M, Pattan J, Santosh D, Manjusha S, Utakarsha et al. Synthesis and evaluation of some novel 2,4thiazolidinedione derivatives for antibacterial, antitubercular and antidiabetic activities. Indian Journal of Chemistry 2012; 51B: 1421–5.
- Ceriello A. Thiazolidinediones as anti-inflammatory and antiatherogenic agents. Diabetes Metabolism Research and Reviews 2008; 24: 14–26. https://doi.org/10.1002/dmrr.790
- Malik N, Parasad DN. Synthesis and antimicrobial evaluation of N-substituted-5-benzylidene-2,4-thiazolidinedione derivatives. Iranian Journal of Pharmaceutical Sciences Summer. 2012; 8 (3): 209-14.
- 8. Aneja DK, Lohan P, Arora S, Sharma C. Synthesis of new pyrazolyl-2, 4-thiazolidinediones as antibacterial and antifungal agents. Organic and Medicinal Chemistry Letters 2011; 1: 15. https://doi.org/10.1186/2191-2858-1-15

- 9. Archana K, Neha K. Antibacterial and antifungal evaluation of Mannich bases of 2,4-thiazolidinedione and rhodanine. Der Pharmacia Letter 2016; 8 (12): 143-8.
- Idhayadhulla A, Surendra Kumar R, Jamal Abdul Nasser A, Selvin J, Manilal A. Synthesis of some Mannich base derivatives and their antimicrobial activity study. Arabian Journal of Chemistry 2014; 7: 994–9. https://doi.org/ 10.1016/j.arabjc.2010.12.025
- Ramit K, Rashmi A, Ravinesh M, Manu A, Pooja M. Synthesis of novel mannich bases of pioglitazone. Current Research in Chemistry 2014; 6 (1): 10-5. https://doi.org/ 10.3923/crc.2014.10.15
- Akhiles R, Mahesh RD, Shilpa SH, Zarina M, Najeeb M, Rohini DD. Synthesis, molecular docking studies and biological evaluation of 5-[4-(substituted) benzylidene] thiazolidine-2,4-dione with their oral hypoglycemic activity. International Research Journal of Pharmacy 2013; 4(8): 151-7. https://doi.org/10.7897/2230-8407.04829
- Kumaraswamy G, Brahmeshwari G, Ravichander M, Uma K. Synthesis, antibacterial and molecular docking studies of new benzimidazole derivatives. Egyptian Journal of Basic and Applied Sciences 2017; 4: 303-9. https://doi.org/ 10.1016/j.ejbas.2017.09.002
- 14. Srikanth R, Sivarajan A, Venkatesan CS, Maheshwaran V, Sugumar P, Rajitha G, Varalakshmi JC, Ponnuswamy MN. Synthesis, characterization, crystal structure, in-vitro antimicrobial evaluation and molecular docking studies of 1-(furan-2-carbonyl)-3-alkyl-2,6-diphenylpiperidin-4-one derivatives. Journal of Molecular Structure 2016; 1125: 481-92. https://doi.org/10.1016/j.molstruc.2016.07.023
- Tamer N, Samir B, Sameh E. Design, synthesis, antimicrobial evaluation and molecular docking studies of some new2,3-dihydrothiazoles and 4-thiazolidinones containing sulfisoxazole. Journal of Enzyme Inhibition and Medicinal Chemistry 2016; 31 (2): 236-46. https://doi.org/10.3109/14756366.2015.1016514
- Ertl P, Bernhard R, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. Journal of Medicinal Chemistry 2000; 43(7): 3714–17. https://doi.org/10.1021/jm000942e
- 17. Haberthur U, Caflisch A. FACTS: Fast analytical continuum treatment of solvation. Journal of Computational Chemistry 2008; 29: 701-15. https://doi.org/10.1002/jcc.20832
- Soujanya M, Rajitha G, Umamaheswari A and Sudheerkumar K. Synthesis, Biological Evaluation and Docking Studies of N-(2-benzamidoferuloyl) Aryl Hydrazone Analogues. Letters in Drug Design & Discovery 2018; 15(8): 875-86 https://doi.org/10.2174/1570180814666171026161041
- 19. Deepak K Aneja, Poonam Lohan, Sanjiv Arora, Chetan Sharma, Kamal R Aneja and Om Prakash. Synthesis of new

- pyrazolyl-2, 4-thiazolidinediones as antibacterial and antifungal agents. Organic and Medicinal Chemistry Letters. 2011; 1:15. https://doi.org/10.1186/2191-2858-1-15
- 20. Sowjanya C, Rama Bharathi V, Kalpana Devi G, Rajitha G. Synthesis and evaluation of some novel 3- [5-phenyl-1,3,4-oxadiazole- 2-yl]-2-(substituted styryl)-quinazoline-4(3H)-ones for antibacterial activity. Journal of Chemical and Pharmaceutical Research 2011; 3(6):212-16.
- Radhe Shyam B, Swastika G, Choowongkomon K, Seetaha S. Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones. DARU Journal of Pharmaceutical Sciences 2015; 23 (6).
- Nikhil MP, Krunal VJ. Microbial studies of N-chloro aryl acetamide substituted thaizole and 2,4-thiazolidinedione derivatives. Journal of Chemical and Pharmaceutical Research 2012; 4(9):4149-55.

Cite this article as:

Swapna D *et al.* Synthesis, molecular docking studies and antimicrobial activity of Mannich bases of thiazolidine-2,4-diones. Int. Res. J. Pharm. 2018;9(11):138-144 http://dx.doi.org/10.7897/2230-8407.0911274

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IRJP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IRJP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IRJP editor or editorial board members.